Q2055 Idecabtagene vicleucel car
Also known as: Abecma, idecabtagene vicleucel, CAR-T
Idecabtagene vicleucel CAR-T cell immunotherapy for CD19-positive multiple myeloma.
In Plain Language
myeloma fighter; engineered cell therapy
Clinical Context
First BCMA-targeting CAR-T approved for relapsed/refractory multiple myeloma. B-cell maturation antigen (BCMA) expressed on plasma cells.
RVU Information
CPT Q2055 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2055?
CPT Q2055 (Idecabtagene vicleucel car) is a Q Codes code. Idecabtagene vicleucel CAR-T cell immunotherapy for CD19-positive multiple myeloma.
Is Q2055 covered by insurance?
Q2055 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. First BCMA-targeting CAR-T approved for relapsed/refractory multiple myeloma. B-cell maturation antigen (BCMA) expressed on plasma cells.
When is CPT Q2055 used?
First BCMA-targeting CAR-T approved for relapsed/refractory multiple myeloma. B-cell maturation antigen (BCMA) expressed on plasma cells.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.